BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30113453)

  • 1. Dermatomyositis as an extrahepatic manifestation of hepatitis B virus-related hepatocellular carcinoma: A case report and literature review.
    Han J; Wang S; Kwong TNY; Liu J
    Medicine (Baltimore); 2018 Aug; 97(33):e11586. PubMed ID: 30113453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatomyositis Induced by Hepatitis B Virus-related Hepatocellular Carcinoma: A Case Report and Review of the Literature.
    Chou JW; Lin YL; Cheng KS; Wu PY; Reanne Ju T
    Intern Med; 2017; 56(14):1831-1837. PubMed ID: 28717078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma.
    Yang SY; Cha BK; Kim G; Lee HW; Kim JG; Chang SK; Kim HJ
    Korean J Intern Med; 2014 Mar; 29(2):231-5. PubMed ID: 24648807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma.
    Kee SJ; Kim TJ; Lee SJ; Cho YN; Park SC; Kim JS; Kim JC; Kang HS; Lee SS; Park YW
    Rheumatol Int; 2009 Mar; 29(5):595-9. PubMed ID: 18802699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of radiofrequency ablation combined with transarterial chemoembolization and antiviral therapy on the prognosis and quality of life in primary chronic HBV-related liver cancer.
    Lu B; Zhu L; Wang X; Zhong L; Cheng Y; Fan J; Yu L
    J BUON; 2019; 24(5):1979-1984. PubMed ID: 31786864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma: a case report in Peru].
    Cuadros-Torres M; Ganoza-Calero AM; Plácido Z; Prado B J
    Rev Gastroenterol Peru; 2019; 39(4):374-377. PubMed ID: 32097401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
    Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
    Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
    Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues.
    Xuan SY; Xin YN; Chen H; Shi GJ; Guan HS; Li Y
    World J Gastroenterol; 2007 Mar; 13(12):1870-4. PubMed ID: 17465484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
    Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M; Della Corte C; Colombo M
    Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
    Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ
    Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBV-associated intrahepatic cholangiocarcinoma with high serum alpha-fetoprotein: a case report with review of literature.
    Wang C; Jing H; Sha D; Wang W; Chen J; Cui Y; Han J
    BMC Infect Dis; 2016 Jun; 16():295. PubMed ID: 27301956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
    Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
    Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
    Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.